Brintellix vortioxetine regulatory update

H. Lundbeck and partner Takeda said FDA accepted for review an NDA for Brintellix vortioxetine to treat major depressive disorder (MDD). The PDUFA date is Oct. 2, 2013. The serotonin modulator and sti...